Liver Fibrosis Progression to Ascites and Liver Failure:
Treatment Strategies to Halt Fibrosis Progression
Ian Y.H. Chua
1, 2, 3, 4
18 February 2025
Abstract
Liver brosis is a pathological process characterized by excessive accumulation of
extracellular matrix (ECM) components, leading to architectural distortion of the liver
parenchyma (Bataller & Brenner, 2005). Left unchecked, it can progress to cirrhosis,
ascites, portal hypertension, and ultimately liver failure (Rockey et al., 2015). Despite the
availability of treatments targeting the underlying causes of liver injury, brosis often
advances silently until patients present with decompensated cirrhosis. This paper
discusses the pathophysiology of liver brosis progression, the development of ascites
and liver failure, and current and emerging treatment strategies aimed at halting brosis
progression. Evidence from recent studies and clinical trials highlights promising
therapeutic approaches (Younossi et al., 2019; Harrison et al., 2020).
Introduction
Liver brosis results from chronic liver injury induced by various etiologies, including
chronic viral hepatitis (B and C), nonalcoholic fatty liver disease (NAFLD), alcohol-related
liver disease, and autoimmune hepatitis (Bataller & Brenner, 2005). Persistent hepatic
injury activates hepatic stellate cells (HSCs), which produce ECM components, leading
to brosis (Rockey et al., 2015). Progressive brosis disrupts hepatic architecture,
impairs blood ow, and contributes to portal hypertension (Maher et al., 2017). Once
brosis reaches an advanced stage, cirrhosis develops, often complicated by ascites,
variceal bleeding, hepatic encephalopathy, and liver failure (Younossi et al., 2019).
Ascites, the pathological accumulation of uid in the peritoneal cavity, is the most
common complication of cirrhosis and signicantly increases morbidity and mortality
(Harrison et al., 2020). Alarmingly, patients may remain asymptomatic until
decompensation occurs, underscoring the importance of early detection and
intervention to prevent progression (Rockey et al., 2015).
Pathophysiology of Fibrosis Progression to Ascites and Liver Failure
Fibrosis progression results from the imbalance between ECM production and
degradation (Bataller & Brenner, 2005). Chronic injury leads to sustained activation of
HSCs and secretion of brogenic cytokines such as transforming growth factor-beta
(TGF-β) (Rockey et al., 2015). Accumulating ECM impedes sinusoidal blood ow,
increasing intrahepatic resistance and portal venous pressure (Maher et al., 2017).
Elevated portal pressure, along with decreased hepatic synthetic function, causes
splanchnic vasodilation, sodium retention, and subsequent uid accumulation in the
peritoneal cavity, manifesting as ascites (Younossi et al., 2019). If untreated, the
condition progresses to refractory ascites, spontaneous bacterial peritonitis, and
hepatorenal syndrome, ultimately culminating in liver failure (Harrison et al., 2020).
Current Treatment Strategies
Targeting Underlying Etiologies
• Viral Hepatitis: Direct-acting antivirals for hepatitis C and nucleos(t)ide analogs
for hepatitis B can halt brosis progression when administered early (Younossi et
al., 2019).
• Alcohol-Related Liver Disease: Alcohol cessation remains pivotal;
corticosteroids or pentoxifylline may be used in severe alcoholic hepatitis
(Bataller & Brenner, 2005).
• NAFLD/NASH: Lifestyle interventions, including weight loss and exercise,
remain primary therapies. Emerging pharmacologic treatments, such as
obeticholic acid, are under investigation (Younossi et al., 2019; Harrison et al.,
2020).
Antibrotic Therapies
While no antibrotic drugs are currently FDA-approved specically for liver brosis,
several agents show promise:
• Obeticholic Acid: FXR agonist that reduces brosis progression in nonalcoholic
steatohepatitis (NASH) (Younossi et al., 2019).
• Lanibranor: A pan-PPAR agonist shown to improve brosis scores in clinical
trials (Harrison et al., 2020).
• Selonsertib: An ASK1 inhibitor, though phase III trials yielded mixed results
(Harrison et al., 2020).
• Pirfenidone: Known for pulmonary brosis treatment, with emerging data
suggesting potential benets in liver brosis (Maher et al., 2017).
Management of Ascites and Liver Failure
• Dietary Sodium Restriction and Diuretics: First-line therapy includes
spironolactone with or without furosemide (Rockey et al., 2015).
• Large-Volume Paracentesis: For tense ascites, accompanied by albumin
infusion to prevent paracentesis-induced circulatory dysfunction (Maher et al.,
2017).
• Transjugular Intrahepatic Portosystemic Shunt (TIPS): For refractory ascites or
variceal bleeding unresponsive to medical therapy (Harrison et al., 2020).
• Liver Transplantation: The denitive treatment for end-stage liver disease
(Bataller & Brenner, 2005).
Emerging Technologies and Future Directions
Targeted Drug Delivery Systems
• Nanoparticle-Based Delivery: GalNAc-conjugated siRNA therapies targeting
hepatic cells show promise in clinical trials (Nair et al., 2014).
• Antibody-Drug Conjugates: Designed to specically target brogenic cell
populations (Abdelrahman & Abdelrahman, 2019).
Gene and Cell-Based Therapies
• CRISPR/Cas9-Mediated Gene Editing: Targeting genes involved in brogenesis
shows preclinical promise (Yin et al., 2016).
• Mesenchymal Stem Cell Therapy: Oers potential for reversing established
brosis by modulating immune responses and promoting tissue repair (Lai et al.,
2015).
Conclusion
Liver brosis is a progressive condition with potentially fatal consequences, including
ascites and liver failure (Rockey et al., 2015; Maher et al., 2017). Although current
treatment strategies primarily target underlying causes of liver injury, emerging therapies
aimed at directly halting brosis progression hold promise (Younossi et al., 2019;
Harrison et al., 2020). Early detection and intervention are crucial, given the silent
progression of the disease. Continued research and clinical trials are essential to develop
eective antibrotic therapies and improve patient outcomes (Bataller & Brenner, 2005;
Yin et al., 2016).
Acknowledgments
This paper was developed with the assistance of ChatGPT 4.0, which provided insights and renements in the
articulation of philosophical and scientic concepts.
1
Founder/CEO, ACE-Learning Systems Pte Ltd.
2
M.Eng. Candidate, Texas Tech University, Lubbock, TX.
3
M.S. (Anatomical Sciences Education) Candidate, University of Florida College of Medicine, Gainesville, FL.
4
M.S. (Medical Physiology) Candidate, Case Western Reserve University School of Medicine, Cleveland, OH.
References
Abdelrahman, M. M., & Abdelrahman, M. H. (2019). Antibody-drug conjugates targeting
brosis: Advances and prospects. Molecular Pharmaceutics, 16(8), 3424-3434.
https://doi.org/10.1021/acs.molpharmaceut.9b00527
Bataller, R., & Brenner, D. A. (2005). Liver brosis. Journal of Clinical Investigation,
115(2), 209-218. https://doi.org/10.1172/JCI24282
Harrison, S. A., Gawrieh, S., Roberts, K., Schuppan, D., Chalasani, N., Cable, E. E., ... &
Goodman, Z. D. (2020). Selonsertib in patients with compensated cirrhosis due to
NASH. New England Journal of Medicine, 382(12), 1177-1186.
https://doi.org/10.1056/NEJMoa1916575
Lai, R. C., Yeo, R. W. Y., & Lim, S. K. (2015). Mesenchymal stem cell exosomes: The
future for regenerative medicine. Molecular Therapy, 23(5), 812-823.
https://doi.org/10.1038/mt.2015.38
Maher, T. M., Bendstrup, E., Dron, L., Langley, J., Smith, G., & Khalid, A. (2017). Global
incidence and prevalence of idiopathic pulmonary brosis. Respiratory Research, 18(1),
210. https://doi.org/10.1186/s12931-017-0710-4
Nair, J. K., Willoughby, J. L., Chan, A., Charisse, K., Alam, M. R., Wang, Q., ... &
Manoharan, M. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes
in hepatocytes and elicits robust RNAi-mediated gene silencing. Journal of the
American Chemical Society, 136(49), 16958-16961. https://doi.org/10.1021/ja505986a
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015). Fibrosis—A common pathway to organ
injury and failure. New England Journal of Medicine, 372(12), 1138-1149.
https://doi.org/10.1056/NEJMra1300575
Yin, H., Song, C. Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., ... & Anderson, D. G. (2016).
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system
components in vivo. Nature Biotechnology, 34(3), 328-333.
https://doi.org/10.1038/nbt.3471
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., ... &
Harrison, S. A. (2019). Obeticholic acid for the treatment of nonalcoholic
steatohepatitis: interim analysis from a multicenter, randomized, placebo-controlled
phase 3 trial. Lancet, 394(10215), 2184-2196. https://doi.org/10.1016/S0140-
6736(19)33041-7
